BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 16512975)

  • 1. Molecular selection for therapy of patients with non-small-cell lung cancer and impaired performance status: has the time come?
    Lara PN
    Clin Lung Cancer; 2006 Jan; 7(4):232-4. PubMed ID: 16512975
    [No Abstract]   [Full Text] [Related]  

  • 2. [Mechanisms of resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer].
    Zhou CC; Deng XF
    Zhonghua Jie He He Hu Xi Za Zhi; 2007 Feb; 30(2):138-40. PubMed ID: 17445479
    [No Abstract]   [Full Text] [Related]  

  • 3. What phase III trials are needed to improve the treatment of advanced non-small-cell lung cancer?
    Saijo N
    Nat Clin Pract Oncol; 2005 Jun; 2(6):275. PubMed ID: 16264964
    [No Abstract]   [Full Text] [Related]  

  • 4. Shortcomings of current therapies for non-small-cell lung cancer: unmet medical needs.
    Burris HA
    Oncogene; 2009 Aug; 28 Suppl 1():S4-13. PubMed ID: 19680296
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Epidermal growth factor receptor as a target in cancer therapy.
    Kim ES
    J Natl Compr Canc Netw; 2003 Jan; 1 Suppl 1():S87-95. PubMed ID: 19795581
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeted therapies and non-small-cell lung cancer: new developments.
    Gridelli C
    Curr Opin Oncol; 2007 Mar; 19(2):75-7. PubMed ID: 17272976
    [No Abstract]   [Full Text] [Related]  

  • 7. Overview of molecular testing in non-small-cell lung cancer: mutational analysis, gene copy number, protein expression and other biomarkers of EGFR for the prediction of response to tyrosine kinase inhibitors.
    John T; Liu G; Tsao MS
    Oncogene; 2009 Aug; 28 Suppl 1():S14-23. PubMed ID: 19680292
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Epidermal growth factor receptor pathway targeted therapy in patients with aerodigestive malignancies.
    Patel JD
    Curr Opin Oncol; 2006 Nov; 18(6):609-14. PubMed ID: 16988582
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Foreword; challenging the 'one-size-fits-all' approach of chemotherapy and radiotherapy for patients with non-small cell lung cancer.
    Kris MG
    Lung Cancer; 2008 Jun; 60 Suppl 2():S1-2. PubMed ID: 18513578
    [No Abstract]   [Full Text] [Related]  

  • 10. Effect of epidermal growth factor receptor tyrosine kinase domain mutations on the outcome of patients with non-small cell lung cancer treated with epidermal growth factor receptor tyrosine kinase inhibitors.
    Jänne PA; Johnson BE
    Clin Cancer Res; 2006 Jul; 12(14 Pt 2):4416s-4420s. PubMed ID: 16857820
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Biological therapy in non-small-cell lung cancer (NSCLC)].
    Souquet PJ
    Rev Pneumol Clin; 2004 Nov; 60(5 Pt 3):4S53-4S56. PubMed ID: 15687996
    [No Abstract]   [Full Text] [Related]  

  • 12. New targeted therapies for non-small-cell lung cancer: a focus on the epidermal growth factor receptor.
    Crawford J
    J Natl Compr Canc Netw; 2003 Jan; 1 Suppl 1():S78-86. PubMed ID: 19795580
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeted therapy for non-small cell lung cancer.
    Toloza EM; D'Amico TA
    Semin Thorac Cardiovasc Surg; 2005; 17(3):199-204. PubMed ID: 16253823
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combined targeted therapies in non-small cell lung cancer: a winner strategy?
    Cascone T; Gridelli C; Ciardiello F
    Curr Opin Oncol; 2007 Mar; 19(2):98-102. PubMed ID: 17272980
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genetic polymorphisms of the epidermal growth factor and related receptor in non-small cell lung cancer--a review of the literature.
    Araújo A; Ribeiro R; Azevedo I; Coelho A; Soares M; Sousa B; Pinto D; Lopes C; Medeiros R; Scagliotti GV
    Oncologist; 2007 Feb; 12(2):201-10. PubMed ID: 17296816
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Selecting patients for treatment with epidermal growth factor tyrosine kinase inhibitors.
    Bonomi PD; Buckingham L; Coon J
    Clin Cancer Res; 2007 Aug; 13(15 Pt 2):s4606-12. PubMed ID: 17671150
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Epidermal growth factor receptor inhibitors in development for the treatment of non-small cell lung cancer.
    Heymach JV; Nilsson M; Blumenschein G; Papadimitrakopoulou V; Herbst R
    Clin Cancer Res; 2006 Jul; 12(14 Pt 2):4441s-4445s. PubMed ID: 16857825
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeted therapies and non-small-cell lung cancer: work in progress?
    Gridelli C
    Curr Opin Oncol; 2006 Mar; 18(2):132-4. PubMed ID: 16462181
    [No Abstract]   [Full Text] [Related]  

  • 19. Selecting lung cancer patients for treatment with epidermal growth factor receptor tyrosine kinase inhibitors by immunohistochemistry and fluorescence in situ hybridization--why, when, and how?
    Dziadziuszko R; Hirsch FR; Varella-Garcia M; Bunn PA
    Clin Cancer Res; 2006 Jul; 12(14 Pt 2):4409s-4415s. PubMed ID: 16857819
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Complex role of histone deacetylase inhibitors in the treatment of non-small-cell lung cancer.
    Neal JW; Sequist LV
    J Clin Oncol; 2012 Jun; 30(18):2280-2. PubMed ID: 22508823
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.